Kuehn Law says it is investigating Soleno Therapeutics officers and directors
Kuehn Law said it is investigating Soleno Therapeutics leadership after allegations in a federal securities lawsuit about the company’s DCCR program and its commercial prospects.
Kuehn Law, PLLC said on Sept. 2 that it is investigating whether officers and directors of Soleno Therapeutics, Inc. breached fiduciary duties to shareholders.
The shareholder litigation firm said its review stems from allegations in a federal securities lawsuit involving Soleno’s DCCR program, which it described as a potential treatment for Prader-Willi syndrome and hyperphagia. The notice says the allegations include claims that the company misrepresented or failed to disclose safety concerns and other risks tied to the program.
The notice says the claims could affect both the safety profile and commercial prospects of DCCR. Kuehn Law cited allegations that Soleno downplayed or concealed excess fluid retention seen in clinical trial participants, and said the drug may have posed materially greater safety risks than previously disclosed.
The notice also says the allegations extend to the drug’s commercial viability after launch. It claims DCCR faced undisclosed risks including higher patient discontinuation, lower patient adoption, prescriber reluctance, possible adverse regulatory action, and reputational and legal fallout.
Prader-Willi syndrome is a rare genetic disorder, and hyperphagia refers to excessive hunger. The PR Newswire notice did not provide independent confirmation of the underlying securities claims or any court finding.
Kuehn Law said current SLNO holders who bought shares before March 26, 2025 can contact Sophia Anne Silayan by email or phone. The notice also says the firm pays case costs and does not charge investor clients. It includes attorney-advertising language and says prior results do not guarantee similar outcomes.
The notice did not say whether Soleno has responded to the allegations. Kuehn Law said shareholders should contact the firm immediately because there may be limited time to enforce rights.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()